m6A-centered Disease Response Information

General Information of the Disease (ID: M6ADIS0155)
Name
Inflammatory bowel disease
ICD
ICD-11: DD7Z
Full List of Target Gene(s) of This m6A-centered Disease Response
NF-kappa-B inhibitor alpha (Nfkbia)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [1]
Response Summary Colonic mucosal barrier dysfunction is one of the major causes of inflammatory bowel disease (IBD). Mettl14 restricted colonic epithelial cell death by regulating the stability of NF-kappa-B inhibitor alpha (Nfkbia) mRNA and modulating the NF-Kappa-B pathway,suggesting that m6A modification could be a potential therapeutic target for IBD.
Responsed Disease Inflammatory bowel disease [ICD-11: DD7Z]
Target Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
Target Regulation Down regulation
Pathway Response NF-kappa B signaling pathway hsa04064
Cell Process Cell apoptosis
In-vivo Model Mettl14f/f mice were generated as previously described with CRISPR-Cas9 technology by insertion of two loxp sites into Mettl14 genome loci. Mettl14f/f mice without Villin-Cre were used as WT controls (Mettl14 WT) for Mettl14 KO mice. Mettl14f/f mice were crossed with Lgr5-eGFP-IRES-creERT2 (Lgr5-Cre) mice to generate Mettl14 depletion in Lgr5+ stem cells.
References
Ref 1 m(6)A mRNA modification maintains colonic epithelial cell homeostasis via NF-KappaB-mediated antiapoptotic pathway. Sci Adv. 2022 Mar 25;8(12):eabl5723. doi: 10.1126/sciadv.abl5723. Epub 2022 Mar 25.